欧康医药
(833230)
| 流通市值：4.94亿 | | | 总市值：11.24亿 |
| 流通股本：3392.18万 | | | 总股本：7726.73万 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 223,826,491.38 | 132,309,174.89 | 68,240,881.12 | 242,810,197.99 |
| 营业收入 | 223,826,491.38 | 132,309,174.89 | 68,240,881.12 | 242,810,197.99 |
| 二、营业总成本 | 201,402,456.95 | 118,189,219.05 | 59,113,846.37 | 228,406,123.63 |
| 营业成本 | 177,890,087.59 | 104,758,943.25 | 53,466,163.68 | 203,354,903.12 |
| 税金及附加 | 844,855.75 | 844,849.83 | 36,051.58 | 593,524.03 |
| 销售费用 | 2,928,687.34 | 1,377,754.9 | 316,262.36 | 2,209,720.96 |
| 管理费用 | 10,447,827.51 | 6,733,150.21 | 2,475,394.53 | 9,946,973.79 |
| 研发费用 | 9,025,240.8 | 4,408,237.31 | 2,619,655.8 | 13,509,643.28 |
| 财务费用 | 265,757.96 | 66,283.55 | 200,318.42 | -1,208,641.55 |
| 其中:利息费用 | 337,056.61 | 154,011.68 | 102,954.33 | 436,528.18 |
| 其中:利息收入 | -120,423.96 | 114,155.64 | -85,073.27 | 1,691,647.35 |
| 加:公允价值变动收益 | - | 91,426.13 | 69,502.35 | 995,406.31 |
| 加:投资收益 | 879,108.01 | 693,879.42 | 348,851.74 | 928,077.42 |
| 汇兑收益 | 325,511.32 | 304,451.94 | 309,669.3 | 437,472.44 |
| 资产处置收益 | -635,689.34 | -29,461.91 | -110,711.94 | -54,956.79 |
| 资产减值损失(新) | -2,002,103.3 | -449,098.92 | - | -1,293,337.57 |
| 信用减值损失(新) | 718,788.91 | 1,140,300.91 | 126,445.5 | -1,350,906.13 |
| 其他收益 | 1,971,098.42 | 1,350,636.5 | 448,633.06 | 2,719,965.76 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 23,680,748.45 | 17,222,089.91 | 10,319,424.76 | 16,785,795.8 |
| 加:营业外收入 | 2,007.48 | 1,565 | 1,565 | 243.5 |
| 减:营业外支出 | 162,741.14 | 162,741.14 | - | 28,317.5 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 23,520,014.79 | 17,060,913.77 | 10,320,989.76 | 16,757,721.8 |
| 减:所得税费用 | 4,265,220.03 | 3,435,764.14 | 1,759,101.29 | 278,012.7 |
| 六、净利润 | 19,254,794.76 | 13,625,149.63 | 8,561,888.47 | 16,479,709.1 |
| 持续经营净利润 | 19,254,794.76 | 13,625,149.63 | 8,561,888.47 | 16,479,709.1 |
| 归属于母公司股东的净利润 | 19,526,091.61 | 13,847,503.44 | 8,654,939.61 | 16,670,309.28 |
| 少数股东损益 | -271,296.85 | -222,353.81 | -93,051.14 | -190,600.18 |
| (一)基本每股收益 | 0.26 | 0.18 | 0.11 | 0.22 |
| (二)稀释每股收益 | 0.26 | 0.18 | 0.11 | 0.22 |
| 八、其他综合收益 | 49,822.77 | 75,970.96 | - | -23,834.47 |
| 归属于母公司股东的其他综合收益 | 49,822.77 | 75,970.96 | - | -19,067.58 |
| 九、综合收益总额 | 19,304,617.53 | 13,701,120.59 | 8,561,888.47 | 16,455,874.63 |
| 归属于母公司股东的综合收益总额 | 19,575,914.38 | 13,923,474.4 | 8,654,939.61 | 16,651,241.7 |
| 归属于少数股东的综合收益总额 | -271,296.85 | -222,353.81 | -93,051.14 | -195,367.07 |
| 公告日期 | 2024-10-30 | 2024-08-27 | 2024-04-26 | 2024-04-17 |
| 审计意见(境内) | | | | 标准无保留意见 |